Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (331 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-07-06. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: to assessmalariaanemiasafety andand efficacy
  Phrases that lowered it: efficacyresults ofgroupsmaleregimen
• Phase: 2 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 4 (lowers risk) · Design
• Minimum age: 0.5 (lowers risk) · Who can join
• Drug's FAERS reports with a death: 15.2% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 2 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 93.5% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 2 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, infectious disease: Yes (lowers risk) · Disease area
• Sponsor's past trials: 1 (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia NCT02654730 · started 2015 · scored riskier than 5% of active trials terminated
• Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM) NCT02174900 · started 2014 · scored riskier than 6% of active trials completed
• Phase2a Primaquine Dose Escalation Study NCT01743820 · started 2013 · scored riskier than 4% of active trials completed
• Low Dose Primaquine for Clearance of Gametocytes NCT01935882 · started 2013 · scored riskier than 5% of active trials completed
• Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine NCT04411836 · started 2021 · scored riskier than 17% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.